Blinded

Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 7, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Orange, Neoplasm, Bristol Myers Squibb, Calendar, ADC, District court, News, 1836 U.S. Patent Office fire, Clinical trial, Absorption, United States District Court for the Eastern District of Texas, Partnership, Orange Book, Relatlimab, IMDC, Toxicity, Patent, Checkmate, Trial of the century, Acceleration, Breast, Potential, RECIST, Catalent, Software, Tumor microenvironment, SIRP, Antibody, FDA, Progression-free survival, DC, MSN, Douglas v. U.S. District Court ex rel Talk America, Society, Ipilimumab, T helper cell, PDC, RCC, ASCO, OS, CDK7, BMS, Webcast, Investigational New Drug, Royalty payment, ANDA, Initial, ENA, Allele, Cabozantinib, Blinded, LAG-3, Conjugation, Conference, IND, Online shopping, Pharmaceutical industry, Communications satellite, Nivolumab, Exelixis, Patient, Exatecan

In 2022, global cabozantinib franchise net product revenues generated by Exelixis and its partners exceeded $1.9 billion.

Key Points: 
  • In 2022, global cabozantinib franchise net product revenues generated by Exelixis and its partners exceeded $1.9 billion.
  • Based upon cabozantinib-related net product revenues generated by Exelixis’ collaboration partners during the quarter and year ended December 31, 2022, Exelixis earned $33.9 million and $121.4 million, respectively, in royalty revenues.
  • Exelixis expects its partner Sairopa to file an Investigational New Drug application (IND) for ADU-1805 in the first quarter of 2023.
  • Exelixis management will discuss the company’s financial results for the fourth quarter and full year of 2022 and provide a general business update during a conference call beginning at 5:00 p.m.

Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer

Retrieved on: 
Thursday, December 22, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Progression-free survival, EXEL, Blinded, RCC, Sunitinib, Patient, Medical Affairs Bureau, Bristol Myers Squibb, Kidney cancer, TKI, Recurrence, ESMO, ICI, Nivolumab, Neoplasm, Pharmaceutical industry, Exelixis

Exelixis, Inc. (Nasdaq: EXEL) today announced the initiation of STELLAR-304, a phase 3 pivotal trial evaluating zanzalintinib in combination with nivolumab versus sunitinib in patients with advanced non-clear cell renal cell carcinoma (nccRCC).

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) today announced the initiation of STELLAR-304, a phase 3 pivotal trial evaluating zanzalintinib in combination with nivolumab versus sunitinib in patients with advanced non-clear cell renal cell carcinoma (nccRCC).
  • Zanzalintinib, which was adopted as the generic name for XL092, is a next-generation tyrosine kinase inhibitor (TKI) in development for multiple advanced tumor types.
  • “In September at ESMO 2022, we presented zanzalintinib phase 1 data which demonstrated promising clinical activity across a range of tumors with a manageable safety profile.
  • We were particularly encouraged by the activity of zanzalintinib in advanced kidney cancer patients, including patients with non-clear cell subtypes.

EQS-News: MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting

Retrieved on: 
Monday, November 7, 2022
Constellation, FC, Cyclophosphamide, Adult, Bruise, CD19, Flushing, PFS, Dor, ADCC, Fever, Rituximab, Partnership, CD20, RCHOP, Sheraton New Orleans, ADCP, Food, CST, Final Analysis, ASCT, ASH, Rash, BET, Safety, Lenalidomide, Chills, Blinded, Prednisone, TD, JAK, Gene, Cancer, Pharmacokinetics, PET, ORR, Progression-free survival, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Ruxolitinib, Headache, Lymphoid leukemia, Immunotherapy, Arm, Vincristine, Incyte, Apoptosis, Death, Bleeding, Doxorubicin, GLA, Pharmaceutical industry, Medical imaging, Vaccine, Patient, DLBCL, Infection, Tafasitamab, MorphoSys, Primary myelofibrosis

As a global commercial-stage biopharmaceutical company, we use groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients.

Key Points: 
  • As a global commercial-stage biopharmaceutical company, we use groundbreaking science and technologies to discover, develop, and deliver innovative cancer medicines to patients.
  • Pelabresib is being investigated as a treatment for myelofibrosis and has not yet been evaluated or approved by any regulatory authorities.
  • MANIFEST (NCT02158858) is an open-label Phase 2 clinical trial of pelabresib in patients with myelofibrosis.
  • Serious infections, including infections that can cause death, have happened in people during treatments with MONJUVI and after the last dose.

New Study Finds Statistically Significantly Faster Healing Rates for Diabetic Wound Patients Treated with Kerecis Fish Skin

Retrieved on: 
Monday, September 20, 2021
Medical Supplies, Health, Diabetes, Clinical Trials, General Health, Biotechnology, Tendon, Debridement, DRS, DPM, Standard of care, Wound, Sale, Lantis, Randomized controlled trial, DFU, Patient, SOC, MD, Â, Blinded, Skin, Omega-3 fatty acid, Dressing (medical), Ulcer, Effect, Tissue, Treatment, Pharmaceutical industry, Medical imaging

A study published in the peer-reviewed journal Wounds reports statistically significantly higher healing rates for diabetic foot ulcers (DFUs) treated with Kerecis Omega3 fish skin compared to DFUs treated with Fibrocol, a collagen-alginate dressing.

Key Points: 
  • A study published in the peer-reviewed journal Wounds reports statistically significantly higher healing rates for diabetic foot ulcers (DFUs) treated with Kerecis Omega3 fish skin compared to DFUs treated with Fibrocol, a collagen-alginate dressing.
  • Of the patients treated with the Kerecis product , 67% had healed after 12 weeks of treatment versus 32% in the control group.
  • These statistically significant results may give new hope to patients suffering from diabetic foot ulcers and other wounds, explained Kerecis founder and CEO Fertram Sigurjonsson.
  • The doctors in this study documented the healing efficacy of the Kerecis Omega3 fish-skin graft technology.